German Biotech & Pharma Landscape 2026: Heidelberg, Berlin, Mainz

Heidelberg concentrates 10 operators in the directory — tied with Berlin for the highest German city count. The research anchors are EMBL Heidelberg (molecular biology, pan-European research infrastructure) and the German Cancer Research Center (DKFZ). The biologics CDMO layer has AGC Biologics Heidelberg (mRNA + pDNA + microbial services), FyoniBio (biosimilar and biologics development), RHEACELL (stromal cell therapy, regenerative medicine), and TolerogenixX (tolerogenic dendritic cell therapy). Heidelberg Pharma develops antibody-drug conjugates. Hummingbird Diagnostics (miRNA diagnostics) and VERAXA Biotech (biotech R&D) complete the Heidelberg count. Apogenix operates a Berlin-listed address but sits within the Heidelberg pharma ecosystem. The BioRN Life Science Cluster anchors the wider Rhine-Neckar biotech ring, and Affimed (Ladenburg, immediately adjacent) adds immunotherapy capacity. For sponsors running a European biotech search in 2026, Heidelberg is the first-look entry point for research + biologics CDMO combinations.

Berlin concentrates the second 10-operator German biotech cluster. The therapeutics layer includes T-Knife (TCR-T cell therapy for solid tumors), Apogenix (immuno-oncology), and Eckert & Ziegler (radiopharmaceutical and isotope-based therapies). ProBioGen runs cell-line development and high-yield CHO services — an often-contracted European CDMO for antibody-producing cell lines. JPT Peptide Technologies provides peptide tools, immunology assays, and clinical-grade peptides for research and clinical programmes. The cluster infrastructure sits around Campus Berlin-Buch (a major biotech research park) and the Max Delbrück Center for Molecular Medicine. For sponsors searching for German biotech beyond the pharma manufacturers, Berlin offers the highest concentration of therapeutics innovators plus cell-line and peptide tools.

Mainz concentrates the European mRNA innovation story through BioNTech, which moved from pre-2020 platform developer to large-scale commercial mRNA manufacturing during the COVID era and now operates across infectious disease and oncology pipelines. CureVac in Tübingen is the second German mRNA innovator, operating an RNA platform with translational and clinical development activity. Around these two innovators, the German mRNA CDMO and supply layer includes AGC Biologics Heidelberg (published mRNA and pDNA manufacturing), IDT Biologika Dessau-Rosslau (viral vector and vaccine manufacturing), and BioSpring Frankfurt (GMP oligonucleotide supply). The European mRNA & Immunotherapy 2026 brief goes deeper on the mRNA supply chain and how it connects across Germany, Switzerland, and the Nordics.

Three big-pharma anchors headquartered in Germany define the pharma-manufacturing layer the directory surfaces. Bayer Pharmaceuticals in Leverkusen runs a diversified pharma portfolio spanning cardiovascular, oncology, and women’s health with global manufacturing infrastructure. Boehringer Ingelheim (Ingelheim am Rhein) operates as a privately held pharma with strengths in respiratory, cardiometabolic, and CNS therapies, plus a biopharmaceutical manufacturing arm (branded externally as BioXcellence). Merck KGaA (Darmstadt) runs pharma + life-science tools + electronics under one corporate umbrella, with its life-science division as a material European biopharma supply operator. Gerresheimer (Düsseldorf) adds pharmaceutical packaging and glass-container manufacturing that serves the wider European biologics supply chain.

Germany holds seven biologics CDMO operators in the directory — the highest single-country CDMO count among European nations the directory surfaces (Switzerland holds six, Denmark two, Finland five including one platform-stage, Poland three). Rentschler Biopharma (Laupheim) is the clinical-to-commercial biologics CDMO anchor with a published regulatory track record. Vetter Pharma (Ravensburg) operates at large commercial scale for sterile fill-finish of biologics. IDT Biologika (Dessau-Rosslau) runs viral-vector and vaccine manufacturing at commercial scale. ProBioGen (Berlin) adds cell-line development and high-yield CHO services. FyoniBio (Heidelberg) supports biosimilar and biologics development. Wacker Biotech (Halle/Jena) specialises in microbial fermentation. AGC Biologics Heidelberg adds mRNA + pDNA + microbial. Together these seven operators form the German biologics CDMO core — the European CDMO Capacity 2026 brief covers the wider CDMO landscape.

Germany’s research anchors (EMBL Heidelberg, DKFZ, Max Delbrück Center Berlin) feed a large academic-to-industry pipeline. The European research-tools layer the directory surfaces has three German operators of material scale: Eppendorf (Hamburg, laboratory instruments and consumables), Miltenyi Biotec (Bergisch Gladbach, cell therapy platforms and clinical manufacturing tools), and QIAGEN (Hilden, molecular diagnostics and sample-preparation reagents) — all with pan-European distribution. Pharmaceutical logistics runs through four DHL Life Sciences & Healthcare sites (Bonn, Florstadt, Leipzig/Halle, Rheinbach) and two Kuehne+Nagel Healthcare sites (Duisburg, Hauneck). BfArM in Bonn operates as the German drug regulator. Avantor / VWR Germany in Darmstadt anchors reagent and consumables distribution.

Outside the Heidelberg / Berlin / Mainz triangle, Germany holds regional biotech clusters with specific capabilities. Hamburg hosts 5 operators including Evotec (integrated drug discovery), altona Diagnostics (molecular diagnostics), Topas Therapeutics (nanoparticle-tolerance biotech), Indivumed Therapeutics (precision oncology), and Eppendorf as the tools anchor — see the Hamburg city page for the Falkenried campus detail. Munich hosts Medpace Germany (pan-European CRO operations) with adjacent biotech activity around the broader Bavarian pharma ecosystem. Göttingen, Hannover, Freiburg, Planegg-Martinsried, and Düsseldorf add single-operator regional entries. For sponsors building a German biotech footprint beyond the big cities, these regional entries cover specific modalities that the bigger hubs do not match one-to-one.